Allergy Therapeutics PLC Cheryl MacDiarmid appointed to Board of Directors (3553Q)
October 27 2021 - 1:00AM
UK Regulatory
TIDMAGY
RNS Number : 3553Q
Allergy Therapeutics PLC
27 October 2021
Allergy Therapeutics plc
("Allergy Therapeutics" or the "Company")
ALLERGY THERAPEUTICS APPOINTS CHERYL MACDIARMID TO BOARD OF
DIRECTORS
27 OCTOBER 2021: Allergy Therapeutics plc (AIM: AGY), the fully
integrated specialty pharmaceutical group specialising in allergy
vaccines, is pleased to announce the appointment of Cheryl
MacDiarmid as a Non-Executive Director of the Company, with effect
from 27 October 2021. Upon appointment Cheryl will also become a
member of the Audit Committee.
Cheryl has more than 25 years' experience in commercial roles
within the global pharmaceuticals sector. She brings significant
marketing, strategy and management expertise, having worked for
GlaxoSmithKline (GSK) since 1993, where she has focussed mainly on
the commercial aspects of the business, developing a deep knowledge
of sales and marketing operations in North America. Cheryl has
significant senior management experience within GSK, initially in
Canada and then in the US where she led the Respiratory Business
Unit and associated US operations. In 2019 Cheryl was appointed
Senior Vice President and Head, Global Commercial Strategy for ViiV
Healthcare, the joint venture between GSK, Pfizer and Shionogi
which specialises in the development of therapies for HIV.
Peter Jensen, Chairman of Allergy Therapeutics, commented: "We
are delighted to welcome Cheryl to the Board of Allergy
Therapeutics. Cheryl brings highly relevant experience, with her
knowledge of the healthcare sector, expertise in marketing and
commercial strategy, and her understanding of the US market,
especially in the light of our recent announcement that our pivotal
G306 Phase III trial is on track to commence in H2 2022 in US and
Europe. I have no doubt she will be an important contributor to the
Board."
Commenting on her appointment, Cheryl MacDiarmid said: "I am
delighted to be joining the Board of Allergy Therapeutics at an
exciting time for the Company. I look forward to helping the Board
to further strengthen Allergy's leadership in the allergy
immunotherapeutics field, providing innovative products to help
people worldwide."
Additional Disclosures
The following information is disclosed pursuant to Schedule Two
paragraph (g) of the AIM Rules of Companies.
Ms Cheryl Faye MacDiarmid (aged 53) holds or has held the
following current and former directorships in the past five
years:
Current Directorships Former Directorships in the past
five years
PHIVCO UK Limited ViiV Healthcare Finance 1 Limited
----------------------------------
PHIVCO UK II Limited
----------------------------------
ViiV Healthcare Finance Limited
----------------------------------
ViiV Healthcare Overseas Limited
----------------------------------
ViiV Healthcare UK Limited
----------------------------------
ViiV Healthcare Trading Services
UK Limited
----------------------------------
ViiV Healthcare UK (No.3) Limited
----------------------------------
ViiV Healthcare UK (No.4) Limited
----------------------------------
ViiV Healthcare UK (No.5) Limited
----------------------------------
ViiV Healthcare UK (No.6) Limited
----------------------------------
ViiV Healthcare UK (No.7) Limited
----------------------------------
Save as set out above, no further information regarding Cheryl
MacDiarmid is required to be disclosed pursuant to Schedule Two
paragraph (g) of the AIM Rules for Companies.
- ENDS -
For further information, please contact:
Allergy Therapeutics
+44 (0) 1903 845 820
Manuel Llobet, Chief Executive Officer
Nick Wykeman, Chief Financial Officer
Panmure Gordon
+44 (0) 20 7886 2500
Freddy Crossley / Emma Earl / Mark Rogers, Corporate Finance
Rupert Dearden, Corporate Broking
Consilium Strategic Communications
+44 20 3709 5700
Mary-Jane Elliott / David Daley / Davide Salvi / Alex Gunter
allergytherapeutics@consilium-comms.com
Notes for editors:
About Allergy Therapeutics
Allergy Therapeutics is an international commercial
biotechnology group focussed on the treatment and diagnosis of
allergic disorders, including immunotherapy vaccines that have the
potential to cure disease. The Group sells proprietary and third
party products from its subsidiaries in nine major European
countries and via distribution agreements in an additional fourteen
countries. Its broad pipeline of products in clinical development
include vaccines for grass, tree and house dust mite, and peanut
allergy vaccine in pre-clinical development. Adjuvant systems to
boost performance of vaccines outside allergy are also in
development.
Formed in 1999 out of Smith Kline Beecham, Allergy Therapeutics
is headquartered in Worthing, UK with more than 11,000m(2) of
state-of-the-art MHRA-approved manufacturing facilities and
laboratories. The Group, which has achieved 10% compound annual
growth since formation, employs c.500 employees and is listed on
the London Stock Exchange (AIM:AGY). For more information, please
see www.allergytherapeutics.com .
This information is provided by RNS, the news service of the
London Stock Exchange. RNS is approved by the Financial Conduct
Authority to act as a Primary Information Provider in the United
Kingdom. Terms and conditions relating to the use and distribution
of this information may apply. For further information, please
contact rns@lseg.com or visit www.rns.com.
RNS may use your IP address to confirm compliance with the terms
and conditions, to analyse how you engage with the information
contained in this communication, and to share such analysis on an
anonymised basis with others as part of our commercial services.
For further information about how RNS and the London Stock Exchange
use the personal data you provide us, please see our Privacy
Policy.
END
BOAMFBBTMTTTTFB
(END) Dow Jones Newswires
October 27, 2021 02:00 ET (06:00 GMT)
Allergy Therapeutics (LSE:AGY)
Historical Stock Chart
From Mar 2024 to Apr 2024
Allergy Therapeutics (LSE:AGY)
Historical Stock Chart
From Apr 2023 to Apr 2024
